Strasbourg: After years of empty pharmacy shelves and rationed antibiotics, the European Union has agreed on a law meant to make sudden medicine shortages far rarer. On 12 May, negotiators from the European Parliament and the Council struck a provisional deal on the Critical Medicines Act, a regulation that aims to shore up the supply of essential drugs such as antibiotics, insulin and common painkillers.
The shortages the law targets are not abstract. In recent winters, pharmacists across the bloc have struggled to fill prescriptions for children’s antibiotics and basic painkillers, while hospitals have rationed some treatments. Much of the vulnerability stems from a heavy reliance on a small number of manufacturers, often outside Europe, for the active ingredients that go into everyday medicines. A single factory outage or export restriction can ripple across the continent within weeks.
The act tries to attack the problem from several directions. It pushes member states to diversify supply chains and to manufacture more critical medicines and their ingredients within Europe, partly through a framework of industrial “strategic projects” that would receive faster permitting and support to build or expand plants. It makes joint procurement easier, lowering the threshold of countries needed to ask the Commission to buy on their behalf from nine to five — a change that should help smaller states pool their purchasing power. And it obliges public buyers to weigh resilience, not just price, when they award contracts, so the cheapest bid no longer automatically wins if it leaves Europe dangerously dependent on one source.
That last provision marks a quiet shift in philosophy. For two decades, health procurement across the bloc has chased the lowest possible price, a logic that hollowed out domestic production of cheap generics. Building resilience back in will cost money, and someone will have to pay for it — most likely national health budgets already under strain. The European Medicines Agency, which welcomed the political agreement, will take on a larger role in monitoring supply and coordinating responses to looming shortages.
The deal is not yet final. It must still be formally endorsed by both the Council and Parliament and pass legal-linguistic checks before it enters the statute book, and the real test will come in implementation. Strategic projects take years to build, and reshoring active-ingredient production is expensive precisely because manufacturers elsewhere can make these chemicals so cheaply.
Sceptics raise fair questions. Some economists warn that subsidising domestic plants risks propping up uncompetitive producers, and that genuine resilience may be better served by stockpiling and diversifying among trusted partners than by repatriating every supply chain. Others note that the act says less about the high prices of novel patented drugs than about the cheap generics that actually go missing. There are worries beyond the bloc too: pharmacists in the United Kingdom have cautioned that an EU preference for its own supply could push non-members to the back of the queue during the next crunch.
Even so, the direction is clear. After the pandemic exposed how fragile Europe’s medicine supply had become, governments have decided that depending on distant factories for life-saving drugs is a strategic risk, not merely a commercial one. Whether the Critical Medicines Act ends shortages “once and for all,” as its champions claim, will depend less on the text agreed this spring than on how much money and political will follow it.
